| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies
|
Kwiatek, Michal
|
|
|
25 |
7 |
p. 512-519
|
article
|
| 2 |
Antibody Response to Pneumococcal, Influenza, and COVID-19 Vaccination in Patients With Multiple Myeloma
|
Singh, Pranjal
|
|
|
25 |
7 |
p. 527-531
|
article
|
| 3 |
A Real-World Evaluation of Frontline Treatment for Acute Myeloid Leukemia With Azacitidine Plus Venetoclax
|
Brandwein, Joseph
|
|
|
25 |
7 |
p. e435-e442
|
article
|
| 4 |
Clinical Impact of Next-Generation Sequencing of T-Cell Lymphomas: A Single Institution Experience
|
Elghawy, Omar
|
|
|
25 |
7 |
p. 505-511.e2
|
article
|
| 5 |
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis
|
Palandri, Francesca
|
|
|
25 |
7 |
p. e524-e532.e3
|
article
|
| 6 |
Editorial Board
|
|
|
|
25 |
7 |
p. A1-A2
|
article
|
| 7 |
Factors Predicting Spontaneous Regression in Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Diseases
|
Takayama, Kosuke
|
|
|
25 |
7 |
p. e466-e473.e1
|
article
|
| 8 |
Follicular Lymphoma: Paving the Path to Cures Through Philanthropy
|
Smith, Mitchell R.
|
|
|
25 |
7 |
p. e507-e509
|
article
|
| 9 |
Hematological Response to Frontline Treatment in Lower Risk Myelodysplastic Syndromes (LRMDS) is Associated With Better Overall Survival
|
Komrokji, Rami S.
|
|
|
25 |
7 |
p. e487-e490
|
article
|
| 10 |
Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials
|
Moreno, David F.
|
|
|
25 |
7 |
p. 494-504
|
article
|
| 11 |
Matching-Adjusted Indirect Comparison of Daratumumab-Pomalidomide-Dexamethasone and Pomalidomide-Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma
|
Chng, Wee Joo
|
|
|
25 |
7 |
p. e457-e465
|
article
|
| 12 |
Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity
|
Kort, Jeries
|
|
|
25 |
7 |
p. e443-e451.e3
|
article
|
| 13 |
mRNA Expression in DLBCL Patients who are CD20 Dim With an Eye Towards More Thoughtful Design of R/R Trials, Possibly Incorporating BCMA Bite Therapy
|
Hough, Bruce
|
|
|
25 |
7 |
p. 539-541
|
article
|
| 14 |
Narrowing of the Racial Disparities Gap in Survival of Patients With Mycosis Fungoides: A Longitudinal Analysis of the SEER Database
|
Le, Britney
|
|
|
25 |
7 |
p. e501-e506
|
article
|
| 15 |
Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring Dialysis
|
Fotiou, Despina
|
|
|
25 |
7 |
p. 532-538
|
article
|
| 16 |
Outcomes of Peripheral Blood Haploidentical Stem Cell Transplantation With Post-Transplant Cyclophosphamide and Earlier Initiation of Immunosuppression
|
Ma'koseh, Mohammad
|
|
|
25 |
7 |
p. e513-e523.e1
|
article
|
| 17 |
Plasma Cytokine and Chemokine Profiles Predict Efficacy and Toxicity of Anti-CD19 CAR-T Cell Therapy in Large B-Cell Lymphoma
|
Zeng, Fanyuan
|
|
|
25 |
7 |
p. e474-e486.e8
|
article
|
| 18 |
Real-World Data on Outcome of Burkitt Lymphoma and Burkitt Leukemia Treated According to the GMALL B-ALL/NHL 2002 Protocol: A Tertiary Center Experience
|
Kosch, Ricardo
|
|
|
25 |
7 |
p. e533-e540.e2
|
article
|
| 19 |
Real-World Safety and Tolerability of Rapid, 30-Minutes, Intravenous Isatuximab in Patients With Multiple Myeloma
|
Kotb, Rami
|
|
|
25 |
7 |
p. e510-e512
|
article
|
| 20 |
Role of Pulmonary Function Tests to Predict Complications After Chimeric Antigen Receptor T-Cell Therapy
|
Walder, Jeremy
|
|
|
25 |
7 |
p. 520-526
|
article
|
| 21 |
SOHO State of the Art Updates and Next Questions Acute Myeloid Leukemia: Current Status and Next Questions
|
Shah, Vishrut
|
|
|
25 |
7 |
p. 465-475
|
article
|
| 22 |
SOHO State of the Art Updates and Next Questions | Challenging Scenarios in the Management of Myeloproliferative Neoplasms
|
Cannova, Joseph
|
|
|
25 |
7 |
p. 484-493
|
article
|
| 23 |
SOHO State of the Art Updates and Next Questions | Novel Immunotherapy Combinations for the Treatment of Indolent B-Cell Lymphoma
|
Zhuang, Tony Z.
|
|
|
25 |
7 |
p. 455-464
|
article
|
| 24 |
SOHO State of the Art Updates and Next Questions: Treatment Options for Marginal Zone Lymphoma
|
Pirosa, Maria Cristina
|
|
|
25 |
7 |
p. 476-483
|
article
|
| 25 |
Table of Contents
|
|
|
|
25 |
7 |
p. A3-A6
|
article
|
| 26 |
The Monoclonal Gammopathy of Undetermined Significance-Like (MGUS-like) Classifier Stratifies Prognosis in Multiple Myeloma: Results from Real-World Data in Chinese Population
|
Yan, Wenqiang
|
|
|
25 |
7 |
p. e452-e456.e4
|
article
|
| 27 |
Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis
|
McCurdy, Arleigh
|
|
|
25 |
7 |
p. e491-e500.e1
|
article
|
Journal description